Natera Inc

NTRA

Company Profile

  • Business description

    Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

  • Contact

    13011 McCallen Pass
    Building A Suite 100
    AustinTX78753
    USA

    T: +1 650 980-9190

    E: [email protected]

    https://www.natera.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2026

    Employees

    4,434

Stocks News & Analysis

stocks

Goldman Sachs Earnings: Valuations remain stretched

We raise our fair value estimate for Goldman Sachs stock.
stocks

Major ASX listed miners overvalued

We’ve adjusted our fair values after updating our commodity price assumptions.
stocks

Undervalued ASX share with pathway to positive cash flow

Higher sales and a new loan facility increase our conviction.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,192.6014.70-0.16%
CAC 408,258.9454.18-0.65%
DAX 4025,297.1355.26-0.22%
Dow JONES (US)49,359.3383.11-0.17%
FTSE 10010,235.293.65-0.04%
HKSE26,582.52262.44-0.98%
NASDAQ23,515.3914.63-0.06%
Nikkei 22553,433.18502.99-0.93%
NZX 50 Index13,580.29137.81-1.00%
S&P 5006,940.014.46-0.06%
S&P/ASX 2008,872.9010.80-0.12%
SSE Composite Index4,107.916.000.15%

Market Movers